Medicare Oncology Payment Program Could Pressure Part D Prices, Industry Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A new Oncology Payment Model for Medicare will test episode-of-care payment for chemotherapy and offer incentives for keeping costs low, but biopharma firms are concerned that inclusion of Part D-covered cancer drugs in the cost measurement will intensify pressure on prices.
You may also be interested in...
Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes
Manufacturer communications with providers and payers could include real-world evidence and pharmacoeconomic information, associations urge.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.